ARTH Arch Therapeutics Inc

Arch Therapeutics Announces Presentations on AC5 Advanced Wound System at the 2020 Symposium on Advanced Wound Care (SAWC) Fall

Arch Therapeutics Announces Presentations on AC5 Advanced Wound System at the 2020 Symposium on Advanced Wound Care (SAWC) Fall
EN
14/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arch Therapeutics Inc

 PRESS RELEASE

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Sy...

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall) SAWC Fall provides a venue to educate clinicians about AC5 Advanced Wound System, present case studies, and continue strategic meetings with wound care companies. FRAMINGHAM, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Sy...

 PRESS RELEASE

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Sy...

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring) A Study of AC5® Advanced Wound System in Patients with Lower Extremity Wounds to be Featured in a Clinical Poster FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring M...

 PRESS RELEASE

Arch Therapeutics Provides Year End Operational Update

Arch Therapeutics Provides Year End Operational Update Continued Strong Trends in Orders and Paid Claims FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”). During its fourth fiscal quarter, the Company experienced a significant increase i...

 PRESS RELEASE

Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Sy...

Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall) AC5® Advanced Wound System to be Featured in the Hands-On Skills Lab for Clinicians and a Clinical Case Poster Demonstrating Utility in Treatment of Venous Leg Ulcers FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2023 Symposiu...

 PRESS RELEASE

Arch Therapeutics Provides AC5® Commercialization Update

Arch Therapeutics Provides AC5® Commercialization Update Orders and Paid Claims Increasing Since Rollout of Reimbursement Code FRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System. Since the Centers for Medicare and Medicaid Services (“CMS”) established A2020, a Level II Healthcare Common Procedure Coding System (“HCPCS”) code dedicated ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch